Clinical trial NCT02339727: Omega-6/Omega-3 Ratio and Neural Development in Preterm Infants.
Official title: Clinical Trial of the Relation Between Omega-6/Omega-3 Ratio in Formula of Preterm Infants Less Than 1500 Grams and/or Less Than 32 Weeks Gestational Ages and Brunet Lezine Score at 2 Years of Live. Anuvis Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Impaired Psychomotor Development
Keywords: Omega-3
Omega-6
Lead sponsor: Health Research Institute of Santiago
Sponsor class: OTHER
First posted: 2015-01-15
Enrollment: 40
Sex: ALL
Minimum age (years): 1
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SCREENING

Brief summary: It's known that Docosahexaenoic acid DHA and all Polyunsaturated Fatty Acids PUFA are important in neurodevelopment of term and preterm infants. This study tried to determine the utility of a balanced contribution of DHA and Arachidonic acid AA (omega-6/omega-3) in milk formula, with a ratio similar to that found in breastfeeding, equal to 2, in very premature infants less than 1500 grams and / or less than 32 weeks of gestational age. To evaluate values of fatty acids they have in blood and psychomotor development they achieve.

Detailed description: The study took place in a single-center; it is a prospective randomized study of preterm infants less than 1500 grams and/or less than 32 weeks gestational age, admitted to the Neonatal Intensive Care Unit in the University Clinical Hospital of Santiago de Compostela. They were recruited for a period of 14 months (from July 2010 to august 2011) and followed from birth until 2 years of life.

40 children were included and followed in the study. Patients will be assigned randomly into two groups depending on the type of formula they are receiving. The group A of children will receive a formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2. And group B will receive other formula with DHA and ARA, but with a ratio of 1/1.

The classification of group A and B was made by simple random way; one birth in every group, continuously.

Implementation of breastfeeding will be promoted and will be fortified after 7 days of life, when the total amount of breast milk will be more than 1/2 of the total.

When breastfeeding will be insufficient or nonexistent, special formulas for premature babies will be given

During the follow-up of patients, will be measured:

1. - Levels of fatty acids in blood in the first week of life, 3 months, 6 months and 12 months.The determination will be carried out in collaboration with the Hospital de Cruces, Bilbao, Spain.
2. - Evaluation of psychomotor development by Brunet-Lezine scale at 2 years of corrected age.

Eligibility criteria: Inclusion Criteria:

Living infants who were less than 1500 grams and/or less than 32 weeks gestational age, and whose parents accepted and subscribed the informed consent

Exclusion Criteria:

* Preterm infants with any malformation or deformation.
* Extreme preterm infants with gestational age less than 25 weeks.
* Infants whose parents couldn't follow up their children in our study center.
* Preterm infants who had a severe intra ventricular hemorrhage (more than grade 2).
* Premature infants who had severe periventricular leukomalacia (more than grade 2) because the latest two conditions can affect neurodevelopment.
* Finally, we excluded neonates who don't need supplementary milk nutrition, i.e. children with breastfeeding only.

Primary outcomes:
measure: Levels of fatty acids in blood
timeFrame: from July 2010 to august 2012 (from the birth to 1 years old)
Secondary outcomes:
measure: Psychomotor development
timeFrame: from september 2012 to november 2013 (at two years of corrected age)
Other outcomes:
Locations:
Study officials:
References: